2696 — Shanghai Henlius Biotech Share News
0.000.00%
Last trade - 00:00- HK$35.72bn
- HK$39.39bn
- CNY6.67bn
Brief: Shanghai Fosun Pharma Says Privatisation Of Shanghai Henlius Biotech Will Not Proceed
Brief: Shanghai Henlius Biotech Says Application For Phase 1B/2 Clinical Trial Of Hlx43- For Injection In- Combination With Hansizhuang Approved By NMPA
Brief: Shanghai Henlius Biotech Says Collaboration And License Agreement With Palleon
Brief: Fosun Pharmaceutical's Subsidiary Signs Agreement With Palleon
Brief: UBS Group's Short Position In Shanghai Henlius Biotech Reduced To 0% On Dec 2 From 2.07% - HKEX
Brief: Shanghai Henlius Biotech Updates On NDA For New Indication Of Hansizhuang
Brief: Shanghai Henlius Biotech Inc's Application For Phase 1B/2 Clinical Trial Of HLX43- For Injection Approved By NMPA
Brief: Shanghai Henlius Biotech Says New Drug Application For Pertuzumab Biosimilar- HLX11 Accepted By NMPA
Brief: Shanghai Henlius Biotech Says NMPA Approved NDA For New Indication Of Hansizhuang
Brief: Henlius Says It Entered Strategic Collaboration With Al-Tiryaq Al-Khalawi Medical Company
Brief: Shanghai Henlius Biotech Says Biologics License Application For Biosimilar Of Denosumab Hlx14 Accepted By Us FDA
Brief: Shanghai Henlius Biotech Says Serplulimab Injection Received Positive Opinion
Brief: Morgan Stanley's Long Position Shanghai Henlius Biotech H-Shares Reduces To 1.04% On Sept 3 - HKEX
Brief: Shanghai Henlius Biotech Does Not Recommend Distribution Of Any Interim Dividend
Brief: Shanghai Henlius Biotech Posts H1 Revenue Of RMB2,746.1 Mln
Brief: Shanghai Henlius Biotech Says Yingbo Mao Appointed As Vice President And CFO
Shanghai Henlius hits 27-month peak on Fosun's buyout offer at premium
Brief: HKEX Says Trading In H Shares Of Shanghai Henlius Biotech Will Be Resumed On June 25
Brief: Shanghai Henlius Biotech Says Application Made To Stock Exchange For Resumption Of Trading